New York Gov. David Paterson is proposing legislation that would impose a ban on gifts to doctors and require physicians making presentations at CME events to disclose any financial relationships with drug companies.

Wyeth and Elan have suspended a clinical study of their jointly developed Alzheimer's vaccine ACC-001 after a patient receiving the treatment was hospitalized for nearly two weeks with skin ulcers.

Expect AstraZeneca's Crestor to emerge as the big winner in the aftermath of Merck/Schering Plough's Vytorin debacle, primary care physicians (PCPs) said.

Researchers from the Georgia Institute of Technology (GIT) have devised an innovative medication monitoring device that could prove to be a useful tool for pharma researchers and marketers of the future.

The UK's drugs regulatory agency said it would not prosecute GlaxoSmithKline (GSK) for allegedly withholding clinical trials data related to its antidepressant Seroxat (paroxetine), sold in the US under the brand name Paxil.

A new study of prescription antidepressants published this week suggests the drugs may be no more effective than placebo in treating the most common forms of depression.

Schering-Plough posted a fourth quarter loss on charges related to its acquisition of Organon and said it was ready to take action if sales of Vytorin and Zetia decline significantly.

There was good news and bad news for Merck/Schering-Plough following their release of long-delayed and disappointing data from the ENHANCE trial, which found no advantage for Vytorin over simvastatin in retarding the progress of atherosclerosis.

Zetia doesn't even move the needle.

Merck and Schering-Plough conducted several studies of their cholesterol treatment Zetia that raise questions about its risks to the liver but never published the results to those studies, The New York Times reports.